SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- CIPRA.ai, a leader in digital twin and agentic AI-driven precision and personalized chronic disease management, today announced a collaboration with Murata, a global provider of advanced electronic components and sensor technologies, to explore the development of next-generation AI-powered wearable solutions for chronic disease management. "Our collaboration with Murata allows us to move closer to a future where patients receive more proactive, personali

In this free webinar, learn how residual reagents and impurities can be identified, assessed and controlled throughout drug development. The featured speakers will discuss risk-based analytical strategies, fit-for-purpose assays and specification setting for small molecules, biologics and advanced therapies. Attendees will also explore how impurity control strategies can evolve as process and product knowledge increases across development. TORONTO, Sept. 21, 2026 /PRNewswire/ -- In this free web

The Ad Council and the Alzheimer's Association launch newest creative for the Alzheimer's Awareness campaign, helping loved ones identify signs that may be more than normal aging NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Today, the Alzheimer's Association and the Ad Council launched new public service advertisements (PSAs) to help people recognize the early signs of Alzheimer's disease and other dementias in their loved ones. The new " Out of Place " PSAs are the latest creative under the award-

In this free webinar, learn how chemical modifications to prime editing guide RNAs (pegRNAs) can improve editing efficiency while keeping the RNA sequence the same length. The featured speaker will discuss a modification strategy that improves pegRNA stability across multiple cell types while maintaining chemistry, manufacturing and controls (CMC) feasibility. Attendees will also explore how greater pegRNA stability can support stronger editing performance and future prime editing development. T

In this free webinar, learn how complex early-phase studies can be designed to generate meaningful proof-of-concept data and support faster development decisions. The featured speakers will discuss biomarker strategies, integrated data insights and approaches to managing operational complexity while maintaining data quality and scientific rigor. Attendees will also explore how strong early planning and study execution can reduce development risk and support program progression. TORONTO, Sept. 21

- SNTX-2643 was generally well tolerated and demonstrated predictable pharmacokinetics with no clinically significant food effect in healthy participants – - In an exploratory target-engagement analysis, a single 3 mg dose attenuated the brain's response to an experimentally induced psychological stressor at both two and 24 hours with concurrent responses seen in autonomic measures at both time points – - After a single dose, pharmacodynamic activity remained evident at 24 hours as plasma exposu

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeu

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced that it has received wri

Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20th International Symposium on Staphylococci and Staphylococcal Infections LOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specif

Bagsværd, Denmark, 21 September 2026 – Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in weight management and type 2 diabetes. The findings were highlighted at Novo’s Capital Markets Day investor briefing. In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss